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ABSTRACT

A MECHANISTIC STUDY OF AN iPSC MODEL FOR LEIGH’S DISEASE CAUSED BY
MtDNA MUTATAION (8993 T>G)

By, John Patrick Galdun III B.S. (Microbiology) University of Georgia, 2013

A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science
at Virginia Commonwealth University.

Virginia Commonwealth University, 2016

Major Director: Raj R. Rao Ph.D, Associate Professor, Department of Chemical and Life
Science Engineering

Mitochondrial diseases encompass a broad range of devastating disorders that typically
affect tissues with high-energy requirements. These disorders have been difficult to diagnose and
research because of the complexity of mitochondrial genetics, and the large variability seen
among patient populations. We have devised and carried out a mechanistic study to generate a
cell based model for Leigh’s disease caused by mitochondrial DNA mutation 8993 T>G. Leigh’s

x

disease is a multi-organ system disorder that depends heavily on the mutation burden seen within
various tissues. Using new reprogramming and sequencing technologies, we were able to show
that Leigh’s disease patient fibroblasts reprogrammed to induced pluripotent stem cells maintain
the same level of mutation burden seen in the original patient cell line. Mutation burden was
maintained through several passages and spontaneous differentiation. This cell based model
could be useful for future pathogenesis studies, or therapeutic drug screenings in a patient and
tissue specific manner.

CHAPTER 1: INTRODUCTION

A. Mitochondria Structure, Function, and Genetics
1. Structure
Through DNA sequencing technologies and homology analysis, it is theorized that
mitochondria arose from anα-Proteobacterial progenitor that formed an endosymbiotic
relationship with an ancestral type of eukaryotic cell (95, 26). As such, mitochondria share a
structural resemblance to their prokaryotic ancestors; possessing two separate and functionally
unique membranes referred to as the outer membrane and inner membrane (41). The outer
membrane separates the mitochondria from the cytoplasm and surrounds the inner membrane.
Unlike the inner membrane, the outer membrane is rather porous. Ions and small-uncharged
particles are able to flow through membrane protein porins, such as the voltage-dependent anion
channel (4). The inner membrane is the site of the protein complexes responsible for generating
the electrochemical gradient needed for adenosine triphosphate (ATP) synthesis in oxidative
phosphorylation (41). The inner membrane is subdivided into two contiguous regions known as
the inner boundary membrane, which lies close to the outer membrane, and the cristae, which are
folded invaginations of the inner membrane into the interior of the mitochondrion (60). A large
complex of proteins known as the mitochondrial contact site and cristae organizing system is
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responsible for upholding the integrity of the folded cristae, and furthermore, maintaining the
efficiency of energy production (23, 75, 61).
The two membranes divide the mitochondrion into three compartments that serve
different functions, and possess different protein components. The intermembrane space is the
compartment between the outer and inner membrane, where much of the transportation
machinery resides (56). The innermost compartment of the mitochondrion, the matrix, houses the
double stranded circular mitochondrial deoxyribonucleic acid (mtDNA) molecule, as well as
serves as the location for numerous enzymatic reactions, mitochondrial transcription, and
mitochondrial translation carried out by the mitochondrial ribosomes, or mitoribosomes (81).
The cristae delineate the final compartment, which is the cristae lumen. As the cristae membrane
is the site for most of the protein complexes of the respiratory chain, the cristae lumen is the
location where the proton gradient is formed (41). Complex V, or ATP synthase, is directly
responsible for using the energy stored in the electrochemical proton gradient to produce ATP
from adenosine diphosphate (ADP) and phosphate (12). Individual ATP synthases are composed
of more than 20 individual proteins, and ATP synthases form supramolecular dimers and
oligomers in long rows along the strongly curved regions of the cristae membrane (76). These
dimers have been shown to be a universal feature among many mitochondria investigated. If
certain subunits are removed from ATP synthases, dimers are unable to form, and the
mitochondria lack the highly folded cristae that are typical of cristae morphology. From theses
studies, it is clear that ATP synthase plays a role in generating the folded mitochondrial cristae.
Given the importance of ATP synthase in the electron transport chain (ETC), any alterations in
the complex itself or the supramolecular structure it forms could have functional implications on
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the efficiency of oxidative phosphorylation and ultimately play a role in pathophysiological
conditions (59, 76).
Different tissue and cell types show variability in mitochondrial arrangement and
morphology. For instance, neuronal mitochondria are very dynamic and use various cytoskeletal
components and specific motor proteins to move to different areas of the cell when needed (71).
On the other hand, mitochondria of cardiomyocytes display a regular and fixed intracellular
arrangement similar to a crystal (6). Mitochondria can also be found in close association with the
endoplasmic reticulum (ER), which has functional implications that are discussed in a later
section (66). In addition to variance among cell types, mitochondria can be dynamic in number
and morphology within a single cell during times of development, cell cycle stages, or when
exposed to stressors. Mitochondria can be long and filamentous, short and rod-like, and under
conditions of compromised function, small and spherical (42, 35). Fusion and fission reactions
control the number of mitochondria within a cell, and can also control mitochondrial morphology
and organization (5). The heterogeneity in these organelles with regards to shape and
intercellular arrangement can most often be attributed to the various functions and energy
demands required of them by the cell in which they occupy.

2. Function
A recent flourish in mitochondrial research has led to the discovery of additional
important mitochondrial functions. As previously stated, the ER has a special membrane domain
that interacts with the mitochondria referred to as the mitochondria-associated ER membrane.
The proteins and enzymes within this region play important roles in calcium signaling (64).
Mitochondrial calcium uptake has been shown to increase ATP production (53, 9), as well as
3
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buffer the cytosolic calcium concentration (67). Regulation of the intracellular calcium
concentration is critical for transcriptional regulation, metabolic processes, hormone release, and
maintaining cell life or cell death signals (58, 30). Mitochondria also exhibit mechanisms of
either inducing or inhibiting apoptosis.
Apoptosis is a process where cells activate an organized cell suicide pathway leading to
their breakdown and eventual phagocytosis. This is distinct from necrosis, and displays the
morphological characteristics of cell shrinkage, membrane blebbing, and DNA cleavage and
separation into apoptotic bodies with cell surface markers bringing about phagocytosis (39).
Although additional mechanisms exist, the two most commonly characterized are the death
receptor pathway, also known as the extrinsic pathway, and the mitochondrial pathway, also
known as the intrinisic pathway. Both pathways ultimately lead to the activation of caspases,
cysteine proteases that cleave after aspartate residues, which selectively cleave intracellular
components resulting in cell death (65). Numerous cell stresses initiate the mitochondrial
pathway including developmental cues, growth factor deprivation, ER stress, and DNA damage
(27). The mitochondria respond by releasing the apoptosis inducing cytochrome c, as well as
proapoptotic (Bax, Bak) and antiapoptotic (Bcl-2, Bcl-xL) members of the Bcl-2 family. The
delicate interplay of these mitochondrial factors results in a controlled activation of caspases
leading to apoptosis (48, 96, 21).
Mitochondria also play a key role in maintaining cellular redox potential. In order to
establish the electrochemical gradient and generate ATP, a series of redox reactions must take
place, wherein electrons pass along a series of enzymes located in the inner membrane causing
the release of free energy allowing the proton flux from the matrix to the intermembrane space.
The coupling of ATP synthesis to the mitochondrial redox environment remains a topic of
4
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debate. However, these redox reactions leading to oxidative phosphorylation, particularly the
reoxidation of nicotinamide adenine dinucleotide (NADH) to NAD+, have clear implications on
the mitochondrial redox environment (52). Alterations in the mitochondrial redox environment
occur in numerous pathological conditions such as ischemic reperfusion injury and various
cancers highlighting the importance of this mitochondrial function (43, 46).
Mitochondria are most noted for their energy producing capabilities. Rightfully so, as on
average the human body requires 50 kg of ATP turnover daily and the majority of this ATP is
generated by oxidative phosphorylation in the mitochondria (3). The enzyme complexes that
comprise the ETC are comprised of multiple subunits that can be encoded for by the nuclear
DNA or the mtDNA.
3. Genetics
Almost all of the over 3000 proteins in mitochondria are coded for by nuclear DNA,
transcribed, translated by cytosolic ribosomes, and then transported into the mitochondria.
Effective nuclear-mitochondria cross talk is absolutely essential for normal mitochondrial
function (94). Although nuclear DNA encodes for most of the human mitochondrial proteins, the
circular, double stranded, and 16,569 bases in length human mtDNA molecule is responsible for
37 genes including 22 tRNAs, 2 rRNAs, and 13 proteins. Human mtDNA contains very few
introns, and is transcribed polycistronically. There are slight differences in the translation code
that prevent nuclear DNA from being translated by mitoribosomes and vice versa (74). All 13
proteins encoded for by mtDNA form subunits of ETC complexes, and are essential for normal
oxidative phosphorylation.
Mitochondrial genes are not inherited in the same fashion as nuclear genes. There is
evidence to suggest that paternal mitochondria are actively tagged for degradation after
5
Back To Table of Contents

fertilization, and thus only the maternal mtDNA is inherited. This is known as a maternal
inheritance pattern (33, 80). The complete mechanism of inheritance is not entirely understood,
but it is widely accepted to follow a maternal lineage with only rare instances of paternal mtDNA
being present after fertilization.
The total number of mitochondrial genomes varies within different cell types, as well as
within the mitochondria of one cell. Through a video-intensified photon counting microscope
system, it was determined in human ovarian carcinoma cells that mitochondria contain a mtDNA
copy number between 1 and 15 with most of the mitochondria containing between 2 and 6 copies
(70). The total number of genomes per cell of course depends upon the number of mitochondria
in the cell, which is largely dependent on the energy needs of the tissue type. For instance,
leukocytes average 350 mtDNA copies per cell (49); where as myocardial cells average more
than 6,000 mtDNA copies per cell (54). The mitochondrial genome also exhibits heteroplasmy,
which is the presence of more than one type of mtDNA genome within a cell or individual.
Heteroplasmy contributes heavily to certain genetic diseases, where the mutation burden
of mtDNA determines the presence of the disease and occasionally the severity of the condition.
The amount of mutated mtDNA must reach a certain threshold for certain diseases to occur.
Copy number and heteroplasmy have also been implicated in age related illnesses, as both
properties change in a tissue specific manner throughout an individual’s life span (91). The
constant exposure to reactive oxygen species in the mitochondria makes the mtDNA particularly
susceptible to mutations. Given the mitochondria’s diverse functional abilities and complex
genetic control, it is easy to see how slight deviations within mitochondria could lead to
devastating diseases.
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B. Mitochondrial Diseases and Dysfunctions
1. Age Related Diseases
Mitochondrial diseases have a wide spectrum of clinical presentations, as well as a
variety of inheritance patterns such as maternal, Mendelian, or a combination of both. This can
make generating a diagnosis rather difficult, as the same phenotype could be caused by a
different mutation, and the same mutation could lead to a completely different condition
depending on the quantity of the mutated mtDNA, or the cell type in which the mutation resides
(73, 92). Despite this drastic variability, mitochondrial diseases generally affect tissues with
high-energy requirements such the central nervous system, liver, kidneys, endocrine system, and
skeletal and cardiac muscles (19). Dysfunctions within mitochondria most notably contribute to
age related diseases, neurodegenerative diseases, and early and late onset genetic disorders.
The process of aging is still somewhat a mystery, but problems in mitochondria have long
been implicated as a possible causal agent. Aging results in a functional decline in various organ
systems that coincide with a functional decline in the mitochondrial respiratory chain. It is also
known that mtDNA mutations increase in aging animals and humans leading to mitochondrial
dysfunction. An increase in reactive oxygen species (ROS) production is also observed (79).
This has led to what is known as the Mitochondrial Free Radical Theory of Ageing (MFRTA).
This theory attributes an increase in ROS to an increase in mtDNA damage, which leads to
mitochondrial dysfunction and further ROS production ultimately resulting in aging (34). This
theory is based on animal studies that suggest lower ROS levels result in longer lifespans. There
are however some detractors from the MFRTA that suggest an increase in mtDNA mutations is
the actual cause of aging, and the ROS increase is only supplementary. As evidence, studies have
not shown a correlation between antioxidant defenses and life span (8). Further studies are
7
Back To Table of Contents

needed to elucidate the exact mechanisms of aging, but ROS and mtDNA mutation accumulation
both seem to contribute. MtDNA mutations also play a role in several neurodegenerative
diseases.
2. Neurodegenerative Diseases
Spinal Muscular Atrophy (SMA) is a neuromuscular disorder characterized by skeletal
muscle weakness and atrophy as a result of losing lower motor neurons in the spinal cord. Most
cases are caused by a mutation in the survival motor neuron gene (SMN1). The quantity of
mtDNA and respiratory chain enzyme activities are significantly reduced in the patient’s muscle
tissues, which researchers regard as secondary to the original muscle wasting. However, there
have been patients exhibiting the various pathologies associated with SMA while lacking a
mutation in SMN1. These patients have depleted levels of mtDNA or mutations in the
cytochrome c oxidase assembly gene resulting in their clinical phenotype (36). The entirety of
this mechanism is not understood.
Parkinson’s disease (PD) is the second most common neurodegenerative disorder.
Evidence is mounting that mitochondrial dysfunction leads to the nigrostriatal neuronal cell
death seen in both neurotoxin-induced and genetic mutant-associated forms of PD. Neurotoxins
such as paraquat, rotenone, and 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) directly
inhibit mitochondrial complex I activities resulting in PD phenotypes. The neurotoxins also
interfere with mitochondrial dynamic regulations leading to fragmented mitochondria due to
increased fission reactions. The genetic form of PD sees mutations in nuclear genes that
associate with vital mitochondrial functions such as mitophagy, mitochondrial dynamics, redox
signaling, and mitochondrial protein import. As a result, ROS production is increased. Further
evidence for mitochondrial dysfunction as a contributing factor to PD is seen when PD
8
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phenotypes are reduced in animal models as a result of therapeutics targeted to inhibit
mitochondrial dysfunction (50). Mitochondria are being investigated as a possible area of
treatment for PD.
Alzheimer’s Disease (AD) is the most common neurodegenerative disorder, and it is
characterized by a loss of cholinergic neurons leading to memory loss and behavioral
impairments. Amyloid precursor protein and amyloid-β, which are found in mitochondrial
membranes and associate with mitochondrial proteins, are elevated in AD and contribute to
mitochondrial dysfunction. AD patients have mitochondria that produce excess ROS, have
increased permeability, and reduced membrane potential. Excess amyloid precursor protein and
amyloid-β may also affect mitochondrial dynamic fusion/fission, mitophagy, and disrupt the
ETC (57). Potential therapeutics will likely need to address the mitochondrial dysfunction seen
in AD patients.
3. Early and Late Onset Genetic Diseases
Mitochondrial diseases as a whole have a prevalence of 1 in 5000 live births (72).
Diseases may occur as a result of inherited mutations in nDNA or mtDNA, which has a 3-fold
higher mutation rate respectively (86). Due to the multi-functional nature of mitochondria,
mutations leading to dysfunction can result in abnormal calcium signaling, excessive ROS
production, dysregulation of apoptosis, and of course energy deficiencies (97). Many conditions
are multisystemic in nature, but some diseases are specific to one tissue type such as Leber’s
hereditary optic neuropathy (LHON) (74). LHON leads to acute loss of central vision, and is
most commonly the result of one of three possible homoplasmic point mutations in mtDNA
genes that code for subunits in complex I (69). Most conditions, however, are caused by
heteroplasmic mutations, where only some copies of the mtDNA have the mutation.
9
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This is the case with MELAS (mitochondrial encephalomyopathy with lactic acidosis and
stroke like episodes). 80% of MELAS cases are caused by the point mutation m.3243A>G,
which affects mt-tRNALeu(UUR). The mutation results in a decreased rate of protein synthesis
leading to energy deficiencies in addition to the symptoms included in the name of the disease.
Although this mutation is shown to cause MELAS, relatively few patients with this mutation
develop MELAS. Instead, maternally inherited diabetes and deafness (MIDD) is more
commonly seen, as well as a mixture of symptoms from both MELAS and MIDD (55). This
highlights the complexity of mitochondrial diseases, as they are dependent on numerous factors
and often exhibit clinical heterogeneity.
Leigh’s disease (also known as subacute, necrotizing encephalopathy) is a mitochondrial
condition that exhibits the largest genetic heterogeneity, and also shows great phenotypic
variability. Leigh’s disease is characterized by focal, bilateral lesions in the basal ganglia,
thalamus, brainstem, and other areas of the brain. Other symptoms associated with Leigh’s
disease are muscle hypotonia, dystonia, seizures, ataxia, nystagmus, breathing irregularities,
cardiomyopathy, gastrointestinal distress, and many others (2, 22). Mutations in nuclear or
mitochondrial genes that code for subunits of the respiratory chain are the cause of Leigh’s
disease.
This research project focuses on the mutation m.8993 T>G. The mutation is present in
the ATP6 gene of mitochondria, which codes for a subunit of the Fo component of ATP synthase.
The m.8993 T>G mutation results in a substitution of arginine for leucine (85). It was originally
believed that this mutation altered effective proton transfer, as it affects the pore-forming unit of
ATP synthase (28). Other research suggests that the mutation affects the c ring subunits ability to
rotate (77). With a mutation load above 95%, this mutation leads to Leigh’s disease typically
10
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before the age of two. This same mutation at lower loads leads to an adult onset disorder known
as NARP (neurogenic muscle weakness, ataxia, and retinitis pigmentosa). The severity of the
condition is often dependent on the percentage of mutated mtDNA (38). Because the m.8993
T>G form of Leigh’s disease requires such a high percentage of mutated mtDNA and reduced
phenotypes are seen at lower mutation loads, it is conceivable that altering the mutation burden
could serve as a possible therapy. Only palliative care is available for Leigh’s disease and all of
the previously discussed conditions. Mitochondrial dysfunction can lead to a vast amount of
complex diseases. Cell based models provide an effective means of studying these diseases, and
could possibly allow for patient specific treatments.

C. Cell Based Models
1. Cybrid Model
A lack of an effective model for studying mitochondrial disorders has led to a variety of
inventive cell based model strategies in an attempt to mimic disease states. The first generation
of these cell based models was the cytoplasmic hybrid (cybrid), which involved fusing mtDNA
derived from platelets with mtDNA depleted neuroblastoma cells. Cybrids with mtDNA
extracted from patients with AD, PD, and MELAS have been successful in displaying similar
disease phenotypes to their respective pathologies including respiratory chain defects, increased
oxidative stress, and alterations in calcium homeostasis (7, 24, 15). However, the cybrid model
has the limitation that the host cells are tumor cells. These cells would thus be expected to have
an altered cell cycle progression and mitochondrial biogenesis. Also, it is not known to what
degree platelet derived mtDNA matches the genome of other cell types (90).
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A modification of the cybrid model has been used to generate trans-mitochondrial mitomice. In this model, mutated (13997 G>A) mtDNA from mouse lung carcinoma cells was
implanted in mtDNA depleted mouse embryonic stem cells (ESCs). The engineered ESCs were
then implanted into pseudopregnant females, and the progeny were characterized as having
successfully received the mutant mtDNA. The results displayed the expected complex I defects
and lactate overproduction, but to a lesser degree than the mtDNA donor mouse lung carcinoma
cells. In addition, other symptoms that were expected such as ROS overproduction, LHON
phenotypes, and tumor formation were not observed (98). Although this model used ESCs as the
host for the mutated mtDNA as opposed to tumor cells, the results did not fully display the
expected disease state due to some compensatory mechanism. A human cell based model would
need to be produced for further studies.
2. Neural Progenitor Model
An improvement to the cybrid model for investigating neurodegenerative diseases is the
use of human neural progenitor (hNP) cells. Neural progenitor cells can differentiate into
neurons, astrocytes, and oligodendrocytes providing possible models for disease states and
potential therapeutics for various conditions. Neural progenitors can be morphologically
characterized by the formation of radially organized columnar epithelial cells known as “neural
rosettes,” and possess a high nuclear-cytoplasmic ratio indicative of actively dividing cells (13,
20). Gene expression or immunocytochemistry assays for markers such as Nestin, Musashi 1,
SOX2, and polysialylated neural cell adhesion molecule also confirm cells as neural progenitors
(14). Uniform neural progenitor populations can be created from hESCs when supplemented
with select medium components. The development of these procedures was critical in being able
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to generate an unlimited lineage-restricted cell source that can maintain a stable chromosome
number for an effective cell based model (14, 78, 32).
This new technology was used in the development of a model to study the genetic
mitochondrial disease known as Leber’s hereditary optic neuropathy (LHON). In this study,
neural progenitors were treated with dideoxycytidine (ddC), which reduces the endogenous
mtDNA. There was no loss in hNP phenotypic markers after this procedure. The cells were then
transfected with recombinant human mitochondrial transcription factor A complexed with
mtDNA that harbored the pathogenic mtDNA G11778A mutation known to be a causal agent for
LHON. The expression of the pathogenic RNA was confirmed, and the hNPs maintained their
ability to differentiate after the transfection (31). Although successful in recreating this disease
state, the challenges of this process are in ddC treating the hNPs while maintaining their hNP
marker expression, and adequately transfecting the desired mutant DNA. This process may be
difficult to replicate with more complex conditions, and thus alternatives were investigated.
3. Induced Pluripotent Stem Cell Model
Reprogramming technologies allow researchers to create induced pluripotent stem cells
(iPSCs) from adult cell types. These cells types exhibit prolonged self-renewal and the ability to
differentiate into multiple cell lineages. Thus, iPSCs could serve as a cell-based model for drug
screening, understanding disease mechanisms, and engineering patient specific cell lines for
possible therapies (87). Reprogramming was first carried out via retroviral-mediated transfection
of transcription factors known to be necessary for pluripotency (82, 83). Although successful in
generating iPSCs for basic research, there was concern about using this technology for
therapeutic applications, as the viral factors integrate with the genome causing the potential for
cancers to develop. Excisable transposon and non-integrative plasmid strategies were
13
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subsequently developed. These methods resolve the problem of genome integration, but are labor
intensive and produce low yields of iPSCs (93, 68, 51). An improvement to these strategies is the
use of modified mRNAs encoding the reprogramming factors OCT4, SOX2, c-MYC, KLF4, and
LIN28A (93). In addition to taking fewer days and generating higher yields, mRNA
reprogramming allows for dosage control of multiple proteins simultaneously, thus permitting
much more control of the reprogramming process (51). It is also reasonable to conclude that
upon further investigation, direct differentiation procedures can be developed using appropriate
mRNAs (93).
Reprogramming somatic cells from diseased patients to iPSCs has been used to generate
effective cell-based models for neurodegenerative disorders such as SMA, PD, and Amyotrophic
Lateral Sclerosis (99, 1, 16, 11). Recently this method has been applied to the study of cell-type
specific disease phenotypes in the mitochondrial disease MELAS. As previously stated, it is
known that the most common cause of MELAS is a mutation in the mtDNA. Reprograming has
allowed for the study of how the mutation results in varying severities of clinical symptoms (29).
In order for iPSCs to be used as an effective cell based model, it must be verified that
reprogramming has not caused significant alterations to the genome. It has been shown that
retroviral reprogramming led to mtDNA mutations that were not present in parental cells (63).
This is a very important aspect to monitor before conclusions can be made in future studies.
D. Summary
The successful development of reprogramming technologies has enabled researchers to
investigate diseases in a patient and cell specific manner. This method can be particularly useful
in studying conditions that display clinical variability among patients, as well as conditions that
affect certain cell types differently. As both conditions hold true in Leigh’s disease 8993 T>G, it
14
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is our hope to develop an iPSC model that accurately reflects the disease characteristics seen in
the patient from which the original cells were derived.
Early reprogramming methods led to mutations that were not seen in the parent cell.
Because mRNA reprogramming methods are still relatively new, it is not known if this process
alters the genome of the reprogrammed cells. Before more investigative disease studies can be
conducted with our Leigh’s 8993 T>G reprogrammed cell line, it must first be confirmed that the
iPSCs maintain this mutation. Based on the background information, we propose to investigate
the following specific aims.
Specific Aim (I) Detect the presence of the 8993 T>G mtDNA mutation in iPSCs of various
passage numbers and differentiated derivatives.
This preliminary data is essential to ensure that the disease-causing agent is still present in the
reprogrammed cells and differentiated cell types.
Specific Aim (II) Quantify the mutation burden in patient derived fibroblasts, iPSCs of
various passage numbers, and differentiated derivatives.
This data will display the exact percentage of the 8993T>G mutation that is present in the
mtDNA of the original patient derived fibroblasts, iPSCs, and differentiated derivatives.
Experiments under this specific aim focus on investigating if the mutation burden is maintained
through reprogramming, several passages, and differentiation into various cell types. The results
of these experiments could provide support for this method as a viable option of developing
patient specific cell based models to investigate Leigh’s disease 8993 T>G.
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CHAPTER 2: MATERIALS AND METHODS

A. MtDNA Isolation
Before the mtDNA can be sequenced, it must be isolated from whole cell pellets,
purified, and quantified.

Control Cell Lines

Experimental Cell Lines

Human Foreskin Fibroblast passage 13
(BJ fib p13)

Leigh’s Patient Fibroblast passage 7
(FB1 fib p7)

Induced Pluripotent Stem Cell passage 21
(BJ iPSC p21)

Leigh’s Induced Pluripotent Stem Cell
passage 9 (FB1 iPSC p9)
Leigh’s Induced Pluripotent Stem Cell
passage 15 (FB1 iPSC p15)
Leigh’s Induced Pluripotent Stem Cell
passage 21 (FB1 iPSC p21)

Induced Pluripotent Stem Cell that has been
spontaneously differentiated passage 24
(BJ Diff p24)

Leigh’s Induced Pluripotent Stem Cell that
has been spontaneously differentiated
passage 24 (FB1 Diff p24)

Table 1: List of cell samples used in all experiments.
The FB1 samples were derived from a Leigh’s patient donor, and are expected to have the 8993
T>G mutation. All of the BJ samples are expected to have the wild type 8993 T, thus, serving as
the control. All samples will undergo the same processing.
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BJ Diff

FB1 iPSC

FB1 Diff

Figure 1: Schematic of sample derivation prior to our experiments.
The mRNA based reprogramming procedure was carried out according to established protocols
(62), resulting in the generation of iPSCs. Spontaneous differentiation was carried out by
embryoid body formation according to established protocols (37). This form of differentiation
results in cell types from all three germ layers. These procedures were carried out prior to our
experiments.
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Figure 2: Schematic of mtDNA extraction.
First, total DNA was extracted from whole cell pellet. MtDNA was then extracted by
enzymatically degrading all non-circular forms of DNA. Finally, the region of interest within the
ATP6 gene was PCR amplified.
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1. Extracting MtDNA From Whole Cell Pellets
Cell pellets containing approximately 500,000 cells were removed from the freezer to
thaw. The QIAamp DNA mini kit manufacturer protocol was followed to extract total DNA, and
the details can be seen in Appendix i (Qiagen, Valencia, CA, USA). This results in an elution of
80 µL of distilled water (dH2O) and total DNA from all cells. In order to obtain the circular
mtDNA, all other DNA was degraded using the Plasmid-Safe ATP-Dependent DNase
(Epicentre, Madison, WI, USA). This product selectively degrades all non-circular DNA
molecules. The manufacturer recommended mini-preparation protocol was followed, details of
which can be found in Appendix i. The 50 µL solutions containing the mtDNA were further
treated with 1 µL of RNaseA for 1 hour at 37°C to further avoid any non-mtDNA nucleic acids.
It is expected that at this point, the mtDNA should be intact, and all other forms of DNA should
be degraded. The samples were further processed prior to use in sequencing protocols.
2. Further Purification and Gel Extraction
In order to rid the mtDNA samples of previously used enzymes, salts, etc., the samples
were cleaned using the UltraClean 15 DNA Purification Kit (Mo Bio, Carlsbad, CA, USA),
details of the protocol can be found in Appendix ii. To ensure the mtDNA was maintained in a
16kb circle, the samples were run on a 0.8% agarose gel, and the 16kb band that appeared for
each sample was extracted from the gel. The methods for creating and running the gel, as well as
the results can be found in Appendix ii. Because the samples were extracted from an agarose gel,
they needed to be cleaned again using the UltraClean 15 DNA Purification Kit with a slightly
modified protocol to get rid of the agarose, details of which are present in Appendix ii. With the
mtDNA isolated and purified, the samples were prepared for sequencing.
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B. Sample Preparation for Sequencing
The previous procedures resulted in a 30 µL solution of dH2O with an unknown quantity
of mtDNA. The amount of mtDNA needed to be quantified and diluted to meet the specifications
for Sanger sequencing and whole exome next-gen sequencing.
1. Quantification and Dilution
The mtDNA was quantified using a NanoDrop One UV/Vis Spectrophotometer (Thermo
scientific, Wilmington, DE, USA). A blank of 1.5 µL of dH2O was used to establish a zero, and
1.5 µL of each sample was used to find the concentration. Concentration results can be found in
Appendix iii. Exome sequencing requires approximately 25 ng of DNA, and the samples were
diluted accordingly. Sanger sequencing, however, requires the area of interest (Region of ATP6
gene containing 8993) to be PCR amplified, purified, and diluted to a concentration of 10ng/µL.
2. PCR and Preparations for Sanger Sequencing
Primers were generated using the human mtDNA sequence provided by mitomap.org,
and IDT’s PrimerQuest tool (IDT, Coralville, Iowa).
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Gene

Direction

Sequence

GC%

Forward

TATCGAAACCATCAGCCTACTC

45.5

Reverse

GCTTCCAATTAGGTGCATGAG

47.6

ATP 6

Product Length
100 bp

Table 2. Primer information for region of ATP 6
The 100 bp amplified sequence contains the 8993 site.
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A standard PCR was carried out using the Takara Taq PCR Amplification Kit (Clontech,
Mountain View, CA, USA). A detailed protocol of the reaction mixture and the cycle
information can be seen in Appendix iv. 10 µL of the PCR product for each sample was run on a
2% agarose gel to confirm proper amplification of the region of interest. The methods for
creating and running the gel, as well as the results can be found in Appendix ii. After gel
confirmation, the PCR products were cleaned again using the UltraClean 15 DNA Purification
Kit (Mo Bio, Carlsbad, CA, USA). The cleaned PCR products were quantified using a NanoDrop
One UV/Vis Spectrophotometer (Thermo scientific, Wilmington, DE, USA), and diluted to 10
ng/µL with dH2O for Sanger sequencing. Also, the primers were diluted to 20ng/µL for Sanger
sequencing. The results from the NanoDrop analysis are presented in Appendix iii.

22
Back To Table of Contents

Figure 3: Sequence of amplified product.
The 8993 position is denoted with an asterisk. We are expecting all of the BJ derived samples to
have a T at this site, and all of the FB1 samples to have a G at this site.
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C. Sanger Sequencing, Next-gen Sequencing for Whole Exome, and Accompanying
Sequence Analysis
All sequencing was carried out in collaboration with the Virginia Commonwealth
University Nucleic Acids Research Facility.
1. Sanger Sequencing and Analysis
Sequencing reactions were carried out with the forward and reverse primers. The cycle
sequencing reaction was carried out on a 96-capillary 3730XL (Applied Biosystems, Foster City,
CA, USA) with BigDye Taq FS Terminator V 3.1. The genotyping and fragment sizing was done
on a 3130XL (Applied Biosystems, Foster City, CA, USA). Details of the cycle sequencing
reaction and the precipitation protocol can be seen in Appendix v. The files generated from the
sequencing were observed using CodonCode Aligner (CodonCode Corporation, Centerville,
MA, USA).
2. Next-gen Sequencing of Whole Exome and Analysis
The DNA concentration was verified using a Qubit fluorometer (Thermo scientific,
Wilmington, DE, USA). Instead of the standard DNA fragmentation, an enzymatic
fragmentation was performed using the KAPA Frag Enzyme from the KAPA HyperPlus Library
Preparation Kit (KAPA Biosystems, Wilmington, MA, USA). This alternative was performed in
order to increase yield during the fragmentation step. Fragmented DNA was purified using
Ampure beads (Beckman Coulter, Brea, CA, USA). DNA libraries were prepared using the
Accel-NGS 2S Plus DNA Library Kit (Swift Biosciences, Ann Arbor, MI, USA). 10 PCR cycles
were carried out during the Library Amplification step. The final libraries were analyzed with a
2100 Bioanalyzer to assess library size distribution (Agilent Technologies, Santa Clara, CA).
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DNA libraries were quantified with the KAPA Library Quantification Kit to ensure accuracy
(KAPA Biosystems, Wilmington, MA, USA). Based on the qPCR results, the DNA libraries
were compiled in equimolar amounts and sequenced with the HiSeq 2500 using TruSeq v3
reagents according to the 2 x 100 bp protocol (Illumina, San Diego, CA, USA).
The file generated from sequencing was separated out into FASTQ files using bcl2fastq
software version 2.17 (Illumina, San Diego, CA, USA). These files were aligned to the mtDNA
reference human genome 19 with Burrows-Wheeler Alignment Tool (45). The alignment tool
generates Sequence Alignment Map (SAM) files, which are sorted based on the coordinates of
the sequence. The SAM files are then converted to a compressed form, BAM format, using
SAMTools. PCR duplicates were removed from the alignment using the Picard toolkit (Broad
Institutes, Cambridge, MA, USA). Finally, the BAM format files were sent to Atlas2 to generate
variant calling files (VCFs) (Human Genome Sequencing Center, Houston, TX, USA).
Integrative Genomics Viewer (IGV) was used to view the sequences (88), while the VCFs were
viewed with a word processor. The filter settings on the VCFs can be seen in Appendix vi.
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CHAPTER 3: RESULTS

A. Sanger Sequencing Results
It was expected that the 8993 T>G mutation would be present in the original fibroblast
taken from the Leigh’s disease patient, as well as in the iPSCs of various passage numbers and
differentiated cells derived from the patient fibroblast. In order to confirm the presence of the
mutation, the mtDNA was extracted from whole cell pellets, and our region of interest within the
ATP6 gene was PCR amplified. The PCR product was purified and quantified to the appropriate
specification. This allowed for Sanger sequencing of the specific ATP6 region containing the
8993 site. All procedures were conducted as outlined in the materials and methods section.
Sanger sequencing of our samples was necessary to confirm the presence of the disease causing
mutation after reprogramming and spontaneous differentiation. The results demonstrate that the
8993 T>G mutation is present in all FB1 samples (FB1 fib p7, FB1 iPSC p9, FB1 iPSC p15, FB1
iPSC p21, and FB1 Diff p24). (Figure 4-6). Verifying the presence of the mutation was a
necessary step prior to the quantification of mutation burden using Next-gen sequencing for
whole exome.
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Figure 4: Sanger sequencing results of FB1 fibroblast (BJ fibroblast control).
PCR amplified products were Sanger sequenced, and the sequencing results were viewed using
CodonCode Aligner. The mutation is seen in the FB1 fibroblast sample, and not in the BJ
fibroblast sample. The asterisk mark the point mutation.
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Figure 5: Sanger sequencing of FB1 iPSC across multiple passages (BJ iPSC control).
PCR amplified products were Sanger sequenced, and the sequencing results were viewed using
CodonCode Aligner. The mutation is seen in all FB1 iPSC samples, and not in the BJ iPSC
sample. The asterisks mark the point mutations.
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Figure 6: Sanger sequencing of FB1 differentiated (BJ Diff control).
PCR amplified products were Sanger sequenced, and the sequencing results were viewed using
CodonCode Aligner. The mutation is seen in the FB1 differentiated sample, and not in the BJ
differentiated sample. The asterisk marks the point mutation.
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B. Next-gen Sequencing for Whole Exome Results
With the presence of the mutation confirmed, the percentage of mutation burden in each
sample was measured using high-throughput Next-gen sequencing for whole exome. This
strategy has previously been utilized to effectively measure heteroplasmies in the mitochondrial
genome (10, 84, 47). The mtDNA was extracted from whole cell pellets, and then purified before
sequencing. The sequencing results yielded a range of total sequence reads between 388 and
2031 at the 8993 position in the different cell samples. This large of a sample size allows us to be
confident about the percentages measured. As expected, BJ fib, BJ iPSC, and BJ Diff possessed
mostly the wild type thymine with only a few sequences containing the mutated guanine. The
Leigh’s patient sample FB1 fibroblast exhibited the mutation in 85 % of the sequences read. The
iPSCs of various passage numbers and the differentiated cell sample displayed similar mutation
levels with a range of 80-88% (Figure 7 and Table 3).
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Position 8993 Mutation Percentages
100%
90%

Heteroplasmy %

80%
70%
60%
50%
T Wild Type

40%

G Mutation

30%
20%
10%
0%
BJ
fib

BJ
BJ
iPSC Diff

FB1 FB1 FB1 FB1 FB1
fib
p9 p15 p21 Diff

Figure 7: Heteroplasmy data for all samples at position 8993.
The extracted mtDNA was Next-gen sequenced for whole exome. The sequencing results were
compiled, and the results were analyzed with the Integrative Genomics Viewer. This allows us to
view heteroplasmic sequences with an exact measure of the variants. The BJ samples exhibited
very low amounts of the T>G mutation at the 8993 position, and the FB1 samples exhibited a
8993 T>G mutation burden in the range of 80-88%. The variant calling files filter settings can be
seen in Appendix vi.
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Sample Name
BJ fibroblast
BJ iPSC
BJ Differentiated
FB1 fibroblast
FB1 iPSC p9
FB1 iPSC p15
FB1 iPSC p21
FB1 iPSC
Differentiated

Total Number
Sequenced
689
1812
388

8993
T
689
1801
377

8993
G
0
11
9

Percentage of
Mutation
0
1
3

548
1987
2031
589

84
234
305
92

464
1753
1726
497

85
88
85
84

1000

203

797

80

Table 3: Heteroplasmy data for all samples at position 8993.
The extracted mtDNA was Next-gen sequenced for whole exome. The sequencing results were
compiled, and the results were analyzed with the IGV. This allows us to view heteroplasmic
sequences with an exact measure of the variants. The total number of reads per sample at the
8993 position ranged between 388 and 2,031. This is more than enough reads to make accurate
determinations for sample 8993 T>G mutation burden. The BJ samples displayed a mutation
burden between 0-3%, and the FB1 samples displayed a mutation burden between 80-88%. The
variant calling files filter settings can be seen in Appendix vi.
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CHAPTER 4: DISCUSSION AND FUTURE DIRECTIONS

Despite the mitochondrial genome being rather small, effectively researching the
pathogenesis of mitochondrial diseases caused by mtDNA mutations has been difficult. Leigh’s
disease has the added complexity of being dependent upon reaching a threshold of mutation
burden in a tissue specific manner. Our methods included the use of Sanger sequencing, Nextgen sequencing, and subsequent analysis of the results to confirm the presence of the 8993 T>G
mutation in all Leigh’s patient derived cell samples. The mutation was detected in all FB1
samples, and the mutation burden was maintained at a consistently elevated percentage through
reprogramming, several passages, and spontaneous differentiation. Thus, our experiments have
resulted in the creation of an iPSC line with a comparable mutation burden to that of the Leigh’s
patient fibroblast from which it was derived. Generating this cell line with the disease-causing
mutation intact is a very important step in confirming reprogramming technologies as a viable
option of creating a cell based model for Leigh’s disease.
Clinically, Leigh’s disease displays variability among patients and variability among
different tissues within individual patients, which can complicate research. Our cell based model
addresses both of these issues. An iPSC model can be created specific to a patient. The stem cells
could then be directly differentiated into specific cell types of interest such as neurons or
myocytes. Further experiments can be carried out to determine how the disease affects specific
tissues on a molecular basis. This is a promising approach for the investigation of patient and
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tissue specific pathophysiology, and for generating possible therapeutics for individual patients
affected by Leigh’s disease and other mitochondrial diseases. The methods used in this study to
successfully create this disease model could also be slightly altered in order to investigate other
mitochondrial diseases.
In addition to confirming the consistent mutation burden of 8993 T>G, the Next-gen
sequencing results also identified a number of other heteroplasmic variants (Table 4). Due to the
highly polymorphic nature of the mitochondrial genome, a number of these variants are
characterized as normal sequence variants that are not likely to contribute to Leigh’s disease.
Some of the variants displayed in the FB1 patient samples were also present in the BJ control
samples in similar quantites (Table 5). Thus, it is unlikely that these sequence variants contribute
to Leigh’s disease. Two other variants in the FB1 patient samples were also present in the BJ
control samples, but in lower quantities (Table 6). When cross examined with the MitoMap
reference, both of these sites were determined to be normal polymorphisms. Also, a number of
sequence variants were associated with previously defined mitochondrial haplogroups. It is
widely known that haplogroup designations are used in population genetics to denote people
with a common ancestory. The haplogroups connected to the FB1 cell line are indicative of
European ancestory, which correlates with the origin of the cell line used in this study (Table 7).
It would be interesting to see if other patients with Leigh’s disease could be connected to similer
haplogroups. This information could be beneficial in identifying at risk populations for Leigh’s
disease.
With the normal variants identified, there were a few remaining sites of interest for
possible future studies (Table 8). The 310 T>C mutation is in the hypervariable II region of the
mitochondrial genome. This control region of the genome is heavily concentrated with
34
Back To Table of Contents

polymorphisms that have inconclusive affects, but the 310 T>C mutation has been implicated in
malignant melanoma, colorectal cancer, and breast cancer (17, 25, 89). The presence of this
mutation is detected in these types of cancer patients at a statistically higher amount when
compared to control populations. This mutation is expected to hinder replication or transcription
of the mitochondrial genome, which could elevate ROS production (89). It is unclear how this
mutation might affect Leigh’s disease.
Another possible variant of interest is 12358 A>G, which is in the ND5 gene coding for
subunit five of NADH dehydrogenase. This mutation is present in a statistically significant
higher number of sporadic Creutzfeldt-Jakob disease cases compared to controls. The mutation is
reported to be correlated with altered brain pH values. It is hypothesized that this could be
caused by a lack of coupling in complex I of the electron transport chain. This variant has not
previously been implicated in Leigh’s disease.
Our research was focused on the 8993 T>G mutation in the ATP6 gene, however, many
Leigh’s disease cases are caused by mutations in genes that code for subunits of complex I.
Next-gen sequencing of the FB1 Leigh’s patient cell line revealed ten sequence variants in genes
that code for subunits of complex I. None of these variants have previously been mentioned as
causes of Leigh’s disease, but it is not inconceivable that they could in some way contribute to
the disease state. Cross referencing these variants with other Leigh’s patient sequencing results
could allow for the determination of their importance to Leigh’s disease.
Our results have opened up a few avenues for future areas of research. Because Leigh’s
disease has more drastic affects on neural cells and myocytes, a possible area of research would
be to directly differentiate our iPSC line into these cell types. Specific transcription factors have
been used to direct differentiation into neural cell types (40). Direct differentiation to
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cardiomyocytes has been difficult in humans, but mouse embryonic fibroblasts have been
directed into cardiomyocytes (18). Differentiation strategies are constantly improving.
Sequencing studies could be performed again to ensure the 8993 T>G mutation is still intact.
In addition to sequencing for heteroplasmies, another interesting area of research could
be connecting the level of mutation burden to the degree of mitochondria dysfunction. Select
biomarkers for mitochondrial dysfunction such as carnitine, pyruvic acid, and lactic acid have
been used in the past to assess mitochondrial respiration. However, a technology has been
developed that allows mitochondrial respiration and glycolysis to be measured simultaneously in
live cells. The Seahorse XF(e)24 Extracellular Flux Analyzer can measure the oxygen
consumption rate and lactic acid production rate, which are very accurate measures of
mitochondrial function. It would be interesting to see if the level of mutation burden
quantitatively altered these measurements (44).
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Heteroplasmic
Variant
Site
72 G>A
149 T>C
*310 T>C
1720 G>A
2707 G>A
4793 A>G
*5231 G>A
*5417 G>A
7028 T>C
*10325 G>A
11719 A>G
*11914 G>A
*12358 A>G
*12372 G>A
12705 T>C
12879 T>C
14766 T>C
15067 T>C
16172 C>T
16184 C>A
16257 C>T
16295 C>T

Locus

FB1 fib
%

FB1 p9
%

FB1 p15
%

FB1 p21
%

FB1 Diff
%

MitoMap
Reference

HVII
HVII
HVII
RNR2
RNR2
ND2
ND2
ND2
COX1
ND3
ND4
ND4
ND5
ND5
ND5
ND5
CYTB
CYTB
HVI
HVI
HVI
HVI

86
90
20
87
88
83
20
21
67
1
82
28
18
21
87
10
81
11
89
83
86
88

100
100
18
97
100
97
0
0
99
0
100
0
0
0
99
0
100
0
100
84
99
99

100
100
28
98
100
99
0
0
99
0
98
0
1
1
99
0
100
0
99
98
99
98

99
100
25
99
100
100
0
1
100
0
100
0
0
0
99
1
99
0
100
99
100
100

97
100
18
96
96
85
1
0
94
18
99
0
1
0
98
0
86
0
100
80
97
95

T
T
T
C
A
A
G
G
C
G
G
G
A
G
C
T
C
T
T
C
C
C

Table 4: Other sites of heteroplasmic variants in Leigh’s patient cell line.
The extracted mtDNA was Next-gen sequenced for whole exome. The sequencing results were
compiled, and the results were analyzed with the Integrative Genomics Viewer. This allows us to
view heteroplasmic sequences with an exact measure of the variants. In addition to the 8993 site,
the sequencing results yielded a number of other variants when compared to the human genome
19 reference. Yellow highlighted variant sites indicate that the control samples contained this
variant with similar percentages. Green highlighted variant sites indicate that the control samples
contained this variant, however, the percentages of the variant in the control samples were much
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lower than the percentages in the FB1 samples. The MitoMap nucleotide was included to
provided a secondary reference sequence. The variant calling files filter settings can be seen in
Appendix vi.
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Heteroplasmic
Variant
Site
149 T>C
12705 T>C
16172 C>T
16184 C>A

Locus
HVII
ND5
HVI
HVI

FB1 FB1 FB1
fib
p9 p15
%
%
%
90 100 100
87
99
99
89 100 99
83
84
98

FB1
p21
%
100
99
100
99

FB1
Diff
%
100
98
100
80

BJ
fib
%
99
99
100
97

BJ
BJ
iPSC Diff
%
%
100 100
100 100
100 100
88
91

MitoMap
Reference
T
C
T
C

Table 5: Heteroplasmic variants in Leigh’s patient cell line similar in BJ control.
The extracted mtDNA was Next-gen sequenced for whole exome. The sequencing results were
compiled, and the results were analyzed with the Integrative Genomics Viewer. These four sites
are the same yellow highlighted sites from Table 4. Because the BJ control samples contain these
variants at similar quantities, it is likely that these are natural variants that do not contribute to
Leigh’s disease. Cross referencing the variants with the MitoMap reference revealed that the
12705 and 16172 sequences are considered normal polymorphisms. The variant calling files
filter settings can be seen in Appendix vi.
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Heteroplasmic
FB1 FB1 FB1 FB1 FB1
Variant
Locus fib
p9 p15 p21 Diff
Site
%
%
%
%
%
2707 G>A
RNR2 88 100 100 100 96
14766 T>C
CYTB 81 100 100 99
86

BJ
Fib
%
0
2

BJ
iPSC
%
1
0

BJ
Diff
%
27
18

MitoMap
Reference
A
C

Table 6: Heteroplasmic variants in Leigh’s patient cell line different in BJ control.
The extracted mtDNA was Next-gen sequenced for whole exome. The sequencing results were
compiled, and the results were analyzed with the Integrative Genomics Viewer. These sites are
the same green highlighted sites from Table 4. Cross referencing the variants with the MitoMap
reference revealed that both 2707 and 14766 are considered normal polymorphisms. The variant
calling files filter settings can be seen in Appendix vi.
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Sequence Variant
4793
7028
11719
12372
12705
12879
14766
16172
16257

Associated Haplogroup(s)
H7
Pre-HV, HV, N, R, U
N, R, U, HV
U
N
U1
Pre-HV, N, R, U
U6
T3

Table 7: Leigh’s patient sequence variant and associated haplogroup.
The extracted mtDNA was Next-gen sequenced for whole exome. The sequencing results were
compiled, and the results were analyzed with the Integrative Genomics Viewer. A number of the
detected variants are associated with defined haplogroups. These haplogroups are associated with
people of European descent, which makes sense as the Leigh’s patient donor is from Europe. It is
unclear as to whether these specific haplogroups are connected to Leigh’s disease.
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Heteroplasmic
Variant
Site
310 T>C
5231 G>A
5417 G>A
10325 G>A
11914 G>A
12358 A>G
12372 G>A

Locus

FB1 fib
%

FB1 p9
%

FB1 p15
%

FB1 p21
%

FB1 Diff
%

MitoMap
Reference

HVII
ND2
ND2
ND3
ND4
ND5
ND5

20
20
21
1
28
18
21

18
0
0
0
0
0
0

28
0
0
0
0
1
1

25
0
1
0
0
0
0

18
1
0
18
0
1
0

T
G
G
G
G
A
G

Table 8: Heteroplasmic variants possibly implicated in Leigh’s disease.
The extracted mtDNA was subjected to whole exome next-gen sequencing. The sequencing
results were compiled, and the results were analyzed with the Integrative Genomics Viewer. This
table includes variants that were not ruled out by virtue of being consistent with the BJ control,
MitoMap reference, or a known haplogroup. Sites 310 and 12358 are associated with other
diseases, but it is unknown as to whether these variants or the any of the others contribute to
Leigh’s disease. The variant calling files filter settings can be seen in Appendix vi.

42
Back To Table of Contents

REFERENCES
1. Badger, J.l., O. Cordero-Llana, E.m. Hartfield, and R. Wade-Martins. "Parkinson's
Disease in a Dish – Using Stem Cells as a Molecular Tool." Neuropharmacology 76
(2014): 88-96.
2. Baertling, F., R. J. Rodenburg, J. Schaper, J. A. Smeitink, W. J. H. Koopman, E.
Mayatepek, E. Morava, and F. Distelmaier. "A Guide to Diagnosis and Treatment of
Leigh Syndrome." Journal of Neurology, Neurosurgery & Psychiatry 85.3 (2013): 25765.
3. Ballmoos, Christoph Von, Alexander Wiedenmann, and Peter Dimroth. "Essentials for
ATP Synthesis by F 1 F 0 ATP Synthases." Annu. Rev. Biochem. Annual Review of
Biochemistry78.1 (2009): 649-72.
4. Bayrhuber, M., T. Meins, M. Habeck, S. Becker, K. Giller, S. Villinger, C. Vonrhein, C.
Griesinger, M. Zweckstetter, and K. Zeth. "Structure of the Human Voltage Dependent
Anion Channel." Proceedings of the National Academy of Sciences (2008).
5. Benard, Giovanni, and Rodrigue Rossignol. "Ultrastructure of the Mitochondrion and Its
Bearing on Function and Bioenergetics." Antioxidants & Redox Signaling 10.8 (2008):
1313-342.
6. Beraud, Nathalie, Sophie Pelloux, Yves Usson, Andrey V. Kuznetsov, Xavier Ronot,
Yves Tourneur, and Valdur Saks. "Mitochondrial Dynamics in Heart Cells: Very Low
Amplitude High Frequency Fluctuations in Adult Cardiomyocytes and Flow Motion in
Non Beating Hl-1 Cells." Journal of Bioenergetics and Biomembranes J Bioenerg
Biomembr 41.2 (2009): 195-214.
7. Borland, M. Kathleen, K.p. Mohanakumar, Jeremy D. Rubinstein, Paula M. Keeney, Jing
Xie, Roderick Capaldi, Lisa D. Dunham, Patricia A. Trimmer, and James P. Bennett.
“Relationships among Molecular Genetic and Respiratory Properties of Parkinson’s
Disease Cybrid Cells Show Similarities to Parkinson’s Brain Tissues.” Biochimica Et
Biophysica Acta (BBA) – Molecular Basis of Disease 1792.1 (2009): 68-74.
8. Bratic, Ana, and Nils-Göran Larsson. "The Role of Mitochondria in Aging." Journal of
Clinical Investigation J. Clin. Invest. 123.3 (2013): 951-57.
9. Brini, Marisa, Paolo Pinton, Michael P. King, Mercy Davidson, Eric A. Schon, and
Rosario Rizzuto. "A Calcium Signaling Defect in the Pathogenesis of a Mitochondrial
DNA Inherited Oxidative Phosphorylation Deficiency." Nature Medicine 5.8 (1999):
951-54.
10. Carroll, C. J., V. Brilhante, and A. Suomalainen. "Next-generation Sequencing for
Mitochondrial Disorders." British Journal of Pharmacology Br J Pharmacol 171.8
(2014): 1837-853.
11. Chen, Hong, Kun Qian, Zhongwei Du, Jingyuan Cao, Andrew Petersen, Huisheng Liu,
Lisle W. Blackbourn, Cindytzu-Ling Huang, Anthony Errigo, Yingnan Yin, Jianfeng Lu,
Melvin Ayala, and Su-Chun Zhang. "Modeling ALS with IPSCs Reveals That Mutant
SOD1 Misregulates Neurofilament Balance in Motor Neurons." Cell Stem Cell 14.6
(2014): 796-809.
43
Back To Table of Contents

12. Davies, K. M., M. Strauss, B. Daum, J. H. Kief, H. D. Osiewacz, A. Rycovska, V.
Zickermann, and W. Kuhlbrandt. "Macromolecular Organization of ATP Synthase and
Complex I in Whole Mitochondria." Proceedings of the National Academy of
Sciences 108.34 (2011): 14121-4126.
13. Dhara, Sujoy K., and Steven L. Stice. "Neural Differentiation of Human Embryonic Stem
Cells." Journal of Cellular Biochemistry J. Cell. Biochem. 105.3 (2008 Oct): 633-40.
14. Dhara, Sujoy K., Kowser Hasneen, David W. Machacek, Nolan L. Boyd, Raj R. Rao, and
Steven L. Stice. "Human Neural Progenitor Cells Derived from Embryonic Stem Cells in
Feeder-free Cultures."Differentiation 76.5 (2008 May): 454-64.
15. Difrancesco, Jacopo C., J. Mark Cooper, Amanda Lam, Paul E. Hart, Lucio Tremolizzo,
Carlo Ferrarese, and Antony H. Schapira. "MELAS Mitochondrial DNA Mutation
A3243G Reduces Glutamate Transport in Cybrids Cell Lines." Experimental
Neurology 212.1 (2008): 152-56.
16. Dimos, J. T., K. T. Rodolfa, K. K. Niakan, L. M. Weisenthal, H. Mitsumoto, W. Chung,
G. F. Croft, G. Saphier, R. Leibel, R. Goland, H. Wichterle, C. E. Henderson, and K.
Eggan. "Induced Pluripotent Stem Cells Generated from Patients with ALS Can Be
Differentiated into Motor Neurons." Science 321.5893 (2008): 1218-221.
17. Ebner, Sabine, Roland Lang, Edith E. Mueller, Waltraud Eder, Michaela Oeller,
Alexandra Moser, Josef Koller, Bernhard Paulweber, Johannes A. Mayr, Wolfgang Sperl,
and Barbara Kofler. "Mitochondrial Haplogroups, Control Region Polymorphisms and
Malignant Melanoma: A Study in Middle European Caucasians." PLoS ONE 6.12 (2011)
18. Efe, Jem A., Simon Hilcove, Janghwan Kim, Hongyan Zhou, Kunfu Ouyang, Gang
Wang, Ju Chen, and Sheng Ding. "Conversion of Mouse Fibroblasts into Cardiomyocytes
Using a Direct Reprogramming Strategy." Nature Cell Biology Nat Cell Biol 13.3 (2011):
215-22.
19. El-Hattab, Ayman W., and Fernando Scaglia. "Mitochondrial Cytopathies." Cell
Calcium (2016).
20. Elkabetz, Y., G. Panagiotakos, G. Al Shamy, N. D. Socci, V. Tabar, and L. Studer.
"Human ES Cell-derived Neural Rosettes Reveal a Functionally Distinct Early Neural
Stem Cell Stage." Genes & Development 22.2 (2008): 152-65.
21. Estaquier, Jérome, François Vallette, Jean-Luc Vayssiere, and Bernard Mignotte. "The
Mitochondrial Pathways of Apoptosis." Advances in Experimental Medicine and Biology
Advances in Mitochondrial Medicine (2011): 157-83.
22. Finsterer, Josef. "Leigh and Leigh-Like Syndrome in Children and Adults." Pediatric
Neurology 39.4 (2008): 223-35.
23. Friedman, Jonathan R., Arnaud Mourier, Justin Yamada, J. Michael Mccaffery, and Jodi
Nunnari. "MICOS Coordinates with Respiratory Complexes and Lipids to Establish
Mitochondrial Inner Membrane Architecture." ELife 4 (2015).
24. Ghosh, Soumitra S., Russell H. Swerdlow, Scott W. Miller, Brina Sheeman, W. Davis
Parker, and Robert E. Davis. "Use of Cytoplasmic Hybrid Cell Lines for Elucidating the
Role of Mitochondrial Dysfunction in Alzheimer's Disease and Parkinson's
Disease." Annals NY Acad Sci Annals of the New York Academy of Sciences 893.1
OXIDATIVE/ENE (1999): 176-91.
25. Govatati, Suresh, Bulle Saradamma, Sravanthi Malempati, Divyamaanasa Dasi, Murali
Krishna Thupurani, Narayana Nagesh, Sisinthy Shivaji, Manjula Bhanoori, Raghava Rao
44
Back To Table of Contents

Tamanam, Varadacharyulu Nallanchakravarthula, and Sreenivasa Rao Pasupuleti.
"Association of Mitochondrial Displacement Loop Polymorphisms with Risk of
Colorectal Cancer in South Indian Population." Mitochondrial DNA Part A (2016): 1-6.
26. Gray, M. W. "Mitochondrial Evolution." Science 283.5407 (1999): 1476-481.
27. Green, Douglas R., and Fabien Llambi. "Cell Death Signaling." Cold Spring Harbor
Perspectives in Biology Cold Spring Harb Perspect Biol 7.12 (2015).
28. Hartzog, P. E., and B. D. Cain. "The Aleu207--arg Mutation in F1F0-ATP Synthase from
Escherichia Coli. A Model for Human Mitochondrial Disease." The Journal of Biological
Chemistry 268.17 (1993): 12250-2252.
29. Hatakeyama, Hideyuki, Ayako Katayama, Hirofumi Komaki, Ichizo Nishino, and YuIchi Goto. "Molecular Pathomechanisms and Cell-type-specific Disease Phenotypes of
MELAS Caused by Mutant Mitochondrial TRNATrp." Acta Neuropathologica
Communications Acta Neuropathol Commun 3.1 (2015).
30. Hayashi, Teruo, Rosario Rizzuto, Gyorgy Hajnoczky, and Tsung-Ping Su. "MAM: More
than Just a Housekeeper." Trends in Cell Biology 19.2 (2009): 81-88.
31. Iyer, S., E. Xiao, K. Alsayegh, N. Eroshenko, M. J. Riggs, J. P. Bennett, and R. R. Rao.
"Mitochondrial Gene Replacement in Human Pluripotent Stem Cell-derived Neural
Progenitors." Gene Therapy Gene Ther 19.5 (2011): 469-75.
32. Iyer, Shilpa, Khaled Alsayegh, Sheena Abraham, and Raj R. Rao. "Stem Cell-Based
Models and Therapies for Neurodegenerative Diseases." Crit Rev Biomed Eng Critical
Reviews™ in Biomedical Engineering 37.4-5 (2009): 321-53.
33. Johns, Donald R. "Paternal Transmission of Mitochondrial DNA Is (fortunately)
Rare." Annals of Neurology Ann Neurol. 54.4 (2003): 422-24.
34. Kandola, K., A. Bowman, and M. A. Birch-Machin. "Oxidative Stress - a Key Emerging
Impact Factor in Health, Ageing, Lifestyle and Aesthetics." International Journal of
Cosmetic Science Int J Cosmet Sci 37 (2015): 1-8.
35. Karbowski, M., and R. J. Youle. "Dynamics of Mitochondrial Morphology in Healthy
Cells and during Apoptosis." Cell Death Differ Cell Death and Differentiation 10.8
(2003): 870-80.
36. Katsetos, Christos D., Sirma Koutzaki, and Joseph J. Melvin. "Mitochondrial
Dysfunction in Neuromuscular Disorders." Seminars in Pediatric Neurology 20.3 (2013):
202-15.
37. Keller, Gordon M. "In Vitro Differentiation of Embryonic Stem Cells." Current Opinion
in Cell Biology 7.6 (1995): 862-69.
38. Keränen, Tapani, and Hanna Kuusisto. "NARP Syndrome and Adultonset Generalised
Seizures." Epileptic Discord 8.3 (2006): 200-03.
39. Kerr, J. F R, A. H. Wyllie, and A. R. Currie. "Apoptosis: A Basic Biological
Phenomenon with Wideranging Implications in Tissue Kinetics." Br J Cancer British
Journal of Cancer 26.4 (1972): 239-57.
40. Kim, Janghwan, Rajesh Ambasudhan, and Sheng Ding. "Direct Lineage Reprogramming
to Neural Cells." Current Opinion in Neurobiology 22.5 (2012): 778-84.
41. Kühlbrandt, Werner. "Structure and Function of Mitochondrial Membrane Protein
Complexes." BMC Biology BMC Biol 13.1 (2015):

45
Back To Table of Contents

42. Kuznetsov, Andrey V., and Raimund Margreiter. "Heterogeneity of Mitochondria and
Mitochondrial Function within Cells as Another Level of Mitochondrial
Complexity." IJMS International Journal of Molecular Sciences 10.4 (2009): 1911-929.
43. Kuznetsov, Andrey V., Yves Usson, Xavier Leverve, and Raimund Margreiter.
"Subcellular Heterogeneity of Mitochondrial Function and Dysfunction: Evidence
Obtained by Confocal Imaging." Molecular and Cellular Biochemistry Mol Cell
Biochem 256.1/2 (2004): 359-65.
44. Lay, Sui, Oana Sanislav, Sarah J. Annesley, and Paul R. Fisher. "Mitochondrial Stress
Tests Using Seahorse Respirometry on Intact Dictyostelium Discoideum Cells." Methods
in Molecular Biology Chemotaxis (2016): 41-61.
45. Li H. (2012) Exploring single-sample SNP and INDEL calling with whole-genome de
novo assembly. Bioinformatics, 28, 1838-1844.
46. Li, Lin Z. "Imaging Mitochondrial Redox Potential and Its Possible Link to Tumor
Metastatic Potential." Journal of Bioenergetics and Biomembranes J Bioenerg
Biomembr 44.6 (2012): 645-53.
47. Li, Mingkun, Anna Schönberg, Michael Schaefer, Roland Schroeder, Ivane Nasidze, and
Mark Stoneking. "Detecting Heteroplasmy from High-Throughput Sequencing of
Complete Human Mitochondrial DNA Genomes." The American Journal of Human
Genetics 87.2 (2010): 237-49.
48. Li, Peng, Deepak Nijhawan, Imawati Budihardjo, Srinivasa M. Srinivasula, Manzoor
Ahmad, Emad S. Alnemri, and Xiaodong Wang. "Cytochrome C and DATP-Dependent
Formation of Apaf-1/Caspase-9 Complex Initiates an Apoptotic Protease
Cascade." Cell 91.4 (1997): 479-89.
49. Liou, C.-W., T.-K. Lin, J.-B. Chen, M.-M. Tiao, S.-W. Weng, S.-D. Chen, Y.-C. Chuang,
J.-H. Chuang, and P.-W. Wang. "Association between a Common Mitochondrial DNA
D-loop Polycytosine Variant and Alteration of Mitochondrial Copy Number in Human
Peripheral Blood Cells." Journal of Medical Genetics 47.11 (2010): 723-28.
50. Luo, Yu, Alan Hoffer, Barry Hoffer, and Xin Qi. "Mitochondria: A Therapeutic Target
for Parkinson’s Disease?" IJMS International Journal of Molecular Sciences 16.9 (2015):
20704-0730.
51. Mandal, Pankaj K., and Derrick J. Rossi. "Reprogramming Human Fibroblasts to
Pluripotency Using Modified MRNA." Nat Protoc Nature Protocols 8.3 (2013): 568-82.
52. Mazat, Jean-Pierre, Stéphane Ransac, Margit Heiske, Anne Devin, and Michel Rigoulet.
"Mitochondrial Energetic Metabolism-some General Principles." IUBMB Life 65.3
(2013): 171-79.
53. Mccormack, James G., and Richard M. Denton. "Intracellular Calcium Ions and
Intramitochondrial Ca in the Regulation of Energy Metabolism in Mammalian
Tissues." Proceedings of the Nutrition Society Proc. Nutr. Soc. 49.01 (1990): 57-75.
54. Miller, F. J. "Precise Determination of Mitochondrial DNA Copy Number in Human
Skeletal and Cardiac Muscle by a PCR-based Assay: Lack of Change of Copy Number
with Age." Nucleic Acids Research31.11 (2003).
55. Nesbitt, V., R. D. S. Pitceathly, D. M. Turnbull, R. W. Taylor, M. G. Sweeney, E. E.
Mudanohwo, S. Rahman, M. G. Hanna, and R. Mcfarland. "The UK MRC Mitochondrial
Disease Patient Cohort Study: Clinical Phenotypes Associated with the M.3243AG
46
Back To Table of Contents

Mutation--implications for Diagnosis and Management." Journal of Neurology,
Neurosurgery & Psychiatry 84.8 (2013): 936-38.
56. Neupert, Walter, and Johannes M. Herrmann. "Translocation of Proteins into
Mitochondria." Annu. Rev. Biochem. Annual Review of Biochemistry 76.1 (2007): 72349.
57. Onyango, Isaac G., Jameel Dennis, and Shaharyah M. Khan. "Mitochondrial Dysfunction
in Alzheimer’s Disease and the Rationale for Bioenergetics Based Therapies."Aging and
Disease A&D 7.2 (2016): 201.
58. Pagliarini, D. J., and J. Rutter. "Hallmarks of a New Era in Mitochondrial
Biochemistry." Genes & Development 27.24 (2013): 2615-627.
59. Paumard, Patrick, Jacques Vaillier, Bénédicte Coulary, Jacques Schaeffer, Vincent
Soubannier, David M. Mueller, Daniel Brèthes, Jean-Paul Di Rago, and Jean Velours.
"The ATP Synthase Is Involved in Generating Mitochondrial Cristae Morphology." The
EMBO Journal 21.3 (2002): 221-30.
60. Perkins, G., C. Renken, M.e. Martone, S.j. Young, M. Ellisman, and T. Frey. "Electron
Tomography of Neuronal Mitochondria: Three-Dimensional Structure and Organization
of Cristae and Membrane Contacts." Journal of Structural Biology 119.3 (1997): 260-72.
61. Pfanner, Nikolaus, Martin Van Der Laan, Paolo Amati, Roderick A. Capaldi, Amy A.
Caudy, Agnieszka Chacinska, Manjula Darshi, Markus Deckers, Suzanne Hoppins, Tateo
Icho, Stefan Jakobs, Jianguo Ji, Vera Kozjak-Pavlovic, Chris Meisinger, Paul R. Odgren,
Sang Ki Park, Peter Rehling, Andreas S. Reichert, M. Saeed Sheikh, Susan S. Taylor,
Nobuo Tsuchida, Alexander M. Van Der Bliek, Ida J. Van Der Klei, Jonathan S.
Weissman, Benedikt Westermann, Jiping Zha, Walter Neupert, and Jodi Nunnari.
"Uniform Nomenclature for the Mitochondrial Contact Site and Cristae Organizing
System." J Cell Biol The Journal of Cell Biology 204.7 (2014): 1083-086.
62. Poleganov, Marco Alexander, Sarah Eminli, Tim Beissert, Stephanie Herz, Jung-Il Moon,
Johanna Goldmann, Arianne Beyer, Rosario Heck, Isabell Burkhart, Diana Barea Roldan,
Özlem Türeci, Kevin Yi, Brad Hamilton, and Ugur Sahin. "Efficient Reprogramming of
Human Fibroblasts and Blood-Derived Endothelial Progenitor Cells Using Nonmodified
RNA for Reprogramming and Immune Evasion." Human Gene Therapy 26.11 (2015):
751-66.
63. Prigione, Alessandro, Björn Lichtner, Heiner Kuhl, Eduard A. Struys, Mirjam Wamelink,
Hans Lehrach, Markus Ralser, Bernd Timmermann, and James Adjaye. "Human IPSCs
Harbor Homoplasmic and Heteroplasmic Mitochondrial DNA Mutations While
Maintaining HESC-Like Metabolic Reprogramming." Stem Cells (2011).
64. Raturi, Arun, and Thomas Simmen. "Where the Endoplasmic Reticulum and the
Mitochondrion Tie the Knot: The Mitochondria-associated Membrane
(MAM)." Biochimica Et Biophysica Acta (BBA) - Molecular Cell Research 1833.1
(2013): 213-24.
65. Riedl, Stefan J., and Yigong Shi. "Molecular Mechanisms of Caspase Regulation during
Apoptosis." Nature Reviews Molecular Cell Biology Nat Rev Mol Cell Biol 5.11 (2004):
897-907.
66. Rizzuto, R. “Close Contacts with the Endoplasmic Reticulum as Determinants of
Mitochondrial Ca2 Responses.” Science 280.5370 (1998): 1763-766.
47
Back To Table of Contents

67. Rizzuto, Rosario, Diego De Stefani, Anna Raffaello, and Cristina Mammucari.
"Mitochondria as Sensors and Regulators of Calcium Signalling." Nature Reviews
Molecular Cell Biology Nat Rev Mol Cell Biol 13.9 (2012): 566-78.
68. Robinton, Daisy A., and George Q. Daley. "The Promise of Induced Pluripotent Stem
Cells in Research and Therapy." Nature 481.7381 (2012): 295-305.
69. Russell, Oliver, and Doug Turnbull. "Mitochondrial DNA Disease—molecular Insights
and Potential Routes to a Cure." Experimental Cell Research 325.1 (2014): 38-43.
70. Satoh, M. "Organization of Multiple Nucleoids and DNA Molecules in Mitochondria of a
Human Cell." Experimental Cell Research 196.1 (1991): 137-40.
71. Saxton, W. M., and P. J. Hollenbeck. "The Axonal Transport of Mitochondria." Journal
of Cell Science 125.9 (2012): 2095-104.
72. Schaefer, Andrew M., Robert W. Taylor, Douglass M. Turnbull, and Patrick F. Chinnery.
"The Epidemiology of Mitochondrial Disorders—past, Present and Future."Biochimica
Et Biophysica Acta (BBA) - Bioenergetics 1659.2-3 (2004): 115-20.
73. Schapira, Anthony Hv. "Mitochondrial Disease." The Lancet 368.9529 (2006): 70-82.
74. Schapira, Anthony Hv. "Mitochondrial Diseases." The Lancet 379.9828 (2012): 1825834.
75. Schmidt, Oliver, Nikolaus Pfanner, and Chris Meisinger. "Mitochondrial Protein Import:
From Proteomics to Functional Mechanisms." Nature Reviews Molecular Cell Biology
Nat Rev Mol Cell Biol 11.9 (2010): 655-67.
76. Seelert, Holger, and Norbert A. Dencher. "ATP Synthase Superassemblies in Animals
and Plants: Two or More Are Better." Biochimica Et Biophysica Acta (BBA) Bioenergetics1807.9 (2011): 1185-197.
77. Sgarbi, Gianluca, Alessandra Baracca, Giorgio Lenaz, Lucia M. Valentino, Valerio
Carelli, and Giancarlo Solaini. "Inefficient Coupling between Proton Transport and ATP
Synthesis May Be the Pathogenic Mechanism for NARP and Leigh Syndrome Resulting
from the T8993G Mutation in MtDNA." Biochem. J. Biochemical Journal 395.3 (2006):
493-500.
78. Shin, Soojung, Maisam Mitalipova, Scott Noggle, Deanne Tibbitts, Alison Venable, Raj
Rao, and Steven L. Stice. "Long-Term Proliferation of Human Embryonic Stem CellDerived Neuroepithelial Cells Using Defined Adherent Culture Conditions." Stem
Cells 24.1 (2006): 125-38.
79. Sun, Nuo, Richard J. Youle, and Toren Finkel. "The Mitochondrial Basis of
Aging." Molecular Cell 61.5 (2016): 654-66.
80. Sutovsky, P. "Ubiquitinated Sperm Mitochondria, Selective Proteolysis, and the
Regulation of Mitochondrial Inheritance in Mammalian Embryos." Biology of
Reproduction 63.2 (2000): 582-90.
81. Taanman, Jan-Willem. "The Mitochondrial Genome: Structure, Transcription,
Translation and Replication." Biochimica Et Biophysica Acta (BBA) Bioenergetics 1410.2 (1999): 103-23.
82. Takahashi, Kazutoshi, and Shinya Yamanaka. "Induction of Pluripotent Stem Cells from
Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors." Cell 126.4 (2006):
663-76.

48
Back To Table of Contents

83. Takahashi, Kazutoshi, Keisuke Okita, Masato Nakagawa, and Shinya Yamanaka.
"Induction of Pluripotent Stem Cells from Fibroblast Cultures." Nat Protoc Nature
Protocols 2.12 (2007): 3081-089.
84. Tang, Sha, and Taosheng Huang. "Characterization of Mitochondrial DNA Heteroplasmy
Using a Parallel Sequencing System." BioTechniques Biotech. 48.4 (2010): 287-96.
85. Tatuch, Y., J. Christodoulou, A. Feigenbaum, J. T. R. Clarke, J. Wherret, C. Smith, N.
Rudd, R. Petrova-Benedict, and B. H. Robinson. "Heteroplasmic MtDNA Mutation (TG)
at 8993 Can Cause Leigh Disease When the Percentage of Abnormal MtDNA Is
High." THe American Society of Human Genetics (1992): 852-58.
86. Taylor, Robert W., and Doug M. Turnbull. "Mitochondrial DNA Mutations in Human
Disease." Nat Rev Genet Nature Reviews Genetics 6.5 (2005): 389-402.
87. Thomson, J. A. "Embryonic Stem Cell Lines Derived from Human
Blastocysts." Science 282.5391 (1998): 1145-147.
88. Thorvaldsdottir, H., J. T. Robinson, and J. P. Mesirov. “Integrative Genomics Viewer
(IGV): High-performance Genomics Data Visualization and Exploration.” Briefings in
Bioinformatics 14.2 (2012): 178-92.
89. Tipirisetti, Nageswara Rao, Suresh Govatati, Priyanka Pullari, Sravanthi Malempati,
Murali Krishna Thupurani, Shyam Perugu, Praveen Guruvaiah, Lakshmi Rao K,
Raghunadha Rao Digumarti, Varadacharyulu Nallanchakravarthula, Manjula Bhanoori,
and Vishnupriya Satti. "Mitochondrial Control Region Alterations and Breast Cancer
Risk: A Study in South Indian Population." PLoS ONE 9.1 (2014)
90. Trimmer, Patricia A., and James P. Bennett. "The Cybrid Model of Sporadic Parkinson's
Disease." Experimental Neurology 218.2 (2009): 320-25.
91. Wachsmuth, Manja, Alexander Hübner, Mingkun Li, Burkhard Madea, and Mark
Stoneking. "Age-Related and Heteroplasmy-Related Variation in Human MtDNA Copy
Number." PLoS Genet PLOS Genetics12.3 (2016).
92. Wallace, D. C. "Mitochondrial Diseases in Man and Mouse." Science 283.5407 (1999):
1482-488.
93. Warren, Luigi, Philip D. Manos, Tim Ahfeldt, Yuin-Han Loh, Hu Li, Frank Lau, Wataru
Ebina, Pankaj K. Mandal, Zachary D. Smith, Alexander Meissner, George Q. Daley,
Andrew S. Brack, James J. Collins, Chad Cowan, Thorsten M. Schlaeger, and Derrick J.
Rossi. "Highly Efficient Reprogramming to Pluripotency and Directed Differentiation of
Human Cells with Synthetic Modified MRNA." Cell Stem Cell 7.5 (2010): 618-30.
94. Wiedemann, N., A. E. Frazier, and N. Pfanner. “The Protein Import Machinery of
Mitochondria.” Journal of Biological Chemistry 279.15 (2004): 14473-4476.
95. Yang, D., Y. Oyaizu, H. Oyaizu, G. J. Olsen, and C. R. Woese. "Mitochondrial
Origins." Proceedings of the National Academy of Sciences 82.13 (1985): 4443-447.
96. Yang, J. "Prevention of Apoptosis by Bcl-2: Release of Cytochrome C from
Mitochondria Blocked." Science 275.5303 (1997): 1129-132.
97. Ylikallio, Emil, and Anu Suomalainen. "Mechanisms of Mitochondrial Diseases." Annals
of Medicine 44.1 (2011): 41-59.
98. Yokota, Mutsumi, Hiroshi Shitara, Osamu Hashizume, Kaori Ishikawa, Kazuto Nakada,
Rie Ishii, Choji Taya, Keizo Takenaga, Hiromichi Yonekawa, and Jun-Ichi Hayashi.
"Generation of Trans-mitochondrial Mito-mice by the Introduction of a Pathogenic
49
Back To Table of Contents

G13997A MtDNA from Highly Metastatic Lung Carcinoma Cells." FEBS Letters 584.18
(2010): 3943-948.
99. Yoshida, Michiko, Shiho Kitaoka, Naohiro Egawa, Mayu Yamane, Ryunosuke Ikeda,
Kayoko Tsukita, Naoki Amano, Akira Watanabe, Masafumi Morimoto, Jun Takahashi,
Hajime Hosoi, Tatsutoshi Nakahata, Haruhisa Inoue, and Megumu K. Saito. "Modeling
the Early Phenotype at the Neuromuscular Junction of Spinal Muscular Atrophy Using
Patient-Derived IPSCs."Stem Cell Reports 4.4 (2015): 561-6
100. Zhang, Jin, Zhi-Xia Zhang, Peng-Chen Du, Wei Zhou, Su-Dong Wu, Qi-Ling Wang,
Cao Chen, Qi Shi, Chen Chen, Chen Gao, Chan Tian, and Xiao-Ping Dong. "Analyses of
the Mitochondrial Mutations in the Chinese Patients with Sporadic Creutzfeldt–Jakob
Disease." Eur J Hum Genet European Journal of Human Genetics 23.1 (2014): 86-91.

50
Back To Table of Contents

APPENDIX

Appendix i: DNA mini kit protocol and mini-preparation ATP-Dependent DNase protocol

Mini kit protocol
1. Centrifuge thawed cell pellet for 5 minutes at 300 x g in a 1.5mL microcentrifuge tube.
2. Remove the supernatant completely and discard without disturbing the cell pellet.
3. Resuspend the cell pellet in 200 µL of phosphate buffered saline (PBS).
4. Add 20 µL of proteinase K.
5. Add 200 µL of buffer AL. Mix by pulse-vortexing for 15 seconds.
6. Incubate solution at 56°C for 10 minutes
7. Centrifuge to remove condensation from the lid.
8. Add 200 µL of 100% ethanol, and pulse-vortex for 15 seconds. Centrifuge to remove
drops from the lid.
9. Apply mixture to QIAamp Mini spin column, and centrifuge at 6,000 x g for 1 minute.
10. Discard the filtrate, and place the spin column in a new collecting tube.
11. Add 500 µL of AW1 buffer to the spin column, and centrifuge at 6,000 x g for 1 minute.
12. Discard the filtrate, and place the spin column in a new collecting tube.
13. Add 500 µL of AW2 buffer to the spin column, and centrifuge at full speed
(approximately 20,000 x g) for 3 minutes.
14. Discard the filtrate, and centrifuge again at full speed for 1 minute.
15. Place the spin column in a clean 1.5 mL microcentrifuge tube, and add 80 µL of nuclease
free water. Incubate for 5 minutes.
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16. Elute by centrifuging at 6,000 x g for 1 min.

Mini-preparation ATP-Dependent DNase protocol
Reaction Mixture

Amount (µL)

Nuclease free H2O with total DNA
25 mM ATP
10X Reaction Buffer
Plasmid-Safe DNase (10U)
Total volume

42
2
5
1
50

1. Incubate the reaction mixture for 30 minutes at 37°C.
2. Inactivate DNase by incubating at 70°C.

Appendix ii: UltraClean 15 DNA Purification protocol and gel protocols

UltraClean 15 DNA purification protocol
Purifying DNA from a solution
1. Determine DNA solution volume (51 µL).
2. Add 3 volumes of ULTRA SALT (153 µL) and mix well.
3. Resuspend ULTRA BIND by vortexing for 1 minute or until homogenous.
4. Add ULTRA BIND. 5 µL plus 1 µL per µg of DNA you expect to recover (6 µL).
5. Incubate for 5 minutes at room temperature. Flick the tube, or invert the tube several time
to insure proper mixing.
6. Centrifuge for 5 seconds, and discard the supernatant.
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7. Let the pellet soak in 1 ml of ULTRA WASH/ETHANOL for 5 minutes. Do not vortex
DNA larger than 15 kb to avoid shearling.
8. Centrifuge for 5 seconds, and discard supernatant.
9. Centrifuge for 5 seconds again, and remove all traces of the ULTRA WASH/ETHANOL.
10. Resuspend the pellet in 30 µL of nuclease free H2O by gently pipetting.
11. Incubate for 5 minutes at room temperature.
12. Centrifuge for 1 minute.
13. Remove supernatant and transfer to a new clean 1.5 mL microcentrifuge tube.

Purifying DNA from a TBE buffered agarose gel
1. Determine weight of agarose gel band slice.
2. Add ½ volume of ULTRA MELT and 4.5 volumes of ULTRA SALT, and mix well.
3. Incubate at 55°C for approximately 5 minutes, or until gel is completely melted.
4. Follow steps 3-13 from the above protocol on purifying DNA from solution.

0.8% agarose gel preparation
1. Dissolve 1.4g of ultra-pure agarose in 175 ml of TBE buffer. Heat until agarose dissolves
completely into solution. Let the solution cool to approximately 50°C.
2. Add 10.5 µL of ethidium bromide and stir under exhaust hood.
3. Pour the gel solution into a gel with the appropriate size gel comb in place. Let the
solution cool.
4. Once the gel has solidified, pull the comb out without breaking the gel.
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5. Mix 20 µL of cleaned up mtDNA with 3.33 µL of loading dye, and load the mix into the
wells.
6. Load an appropriate gel ladder. Run the gel at 30 V for 8-10 hours. Low voltage run to
avoid smearing the large 16 kb band.
7. Use the gel dock reader to extract the band.

2.0% agarose gel preparation
1. Dissolve 2g of ultra-pure agarose in 100 ml of TBE buffer. Heat until agarose dissolves
completely into solution. Let the solution cool to approximately 50°C.
2. Add 6 µL of ethidium bromide and stir under exhaust hood.
3. Pour the gel solution into a gel with the appropriate size gel comb in place. Let the
solution cool.
4. Once the gel has solidified, pull the comb out without breaking the gel.
5. Mix 10 µL of PCR amplified product with 1.67 µL of loading dye, and load the mix into
the wells.
6. Load an appropriate gel ladder. Run the gel at 80 V for 1.5 hours.
7. Use the gel dock reader to record the size of the PCR products.
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0.8% agarose gel results

λ EcoT14i was used as a reference (Clontech, Mountain View, CA, USA)
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2.0 % agarose gel results

Hyperladder ii was used as a reference (Bioline, Taunton, MA, USA).
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Appendix iii: NanoDrop results

NanoDrop concentration results after gel extraction
Sample Name
H9 p54
BJ FB p13
BJ iPSC p21
BJ Diff p24
FB1 p7
FB1 iPSC p9
FB1 iPSC p15
FB1 iPSC p21
FB1 Diff p24

Concentration (ng/µL)
73.1
58.7
281.1
35.6
125.1
79.0
24.6
44.1
31.7

NanoDrop concentration results after PCR amplification
Sample Name
H9 p54
BJ FB p13
BJ iPSC p21
BJ Diff p24
FB1 p7
FB1 iPSC p9
FB1 iPSC p15
FB1 iPSC p21
FB1 Diff p24

Concentration (ng/µL)
88.3
62.5
62.7
35.3
128.8
104.7
38.6
34.3
62.5
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Appendix iv: PCR protocol and cycle information

PCR Reaction Setup

Stock
Conc.

Volume per
50 µl Rxn

Final
Conc.

10x PCR buffer

10

5

1

dNTP mixture

2.5

4

0.2

10uM Forward primer

10

1

0.2

10uM Reverse primer

10

1

0.2

Takara Taq

250

0.25

1.25

dd H20
0.5 ng/50µl DNA

38.25
1

Total volume

7.5

50

Cycling Steps

Temperatures
and Times

Denaturation

30 sec at 94°C

Annealing

30 sec at 55°C

Extension

30 sec at 72°C

Final Extension

2 min at 72°C
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0.5

Cycles

25

1

Appendix v: Cycle sequencing reaction and precipitation protocol
Cycle sequencing reaction for standard quarter reaction
Sequencing Reaction Setup

Amount

Big Dye

2 µl

Primer

X µl 3.2 pmol

Sequencing buff (5X)

1 µl

dd H20

X µl

DNA

X µl 60-100 ng

Total volume

10

Precipitation Protocol
1. Prepare 3 µl sodium acetate anhydrous (3M pH 4.6), 62.5 µl Ethanol (100 %), 14.5 µl
water.
2. Add 10 µl of water to make the sequencing samples up to 20 µl.
3. Mix the sodium acetate anhydrous and ethanol with each sequencing sample.
4. Centrifuge for 30 minutes.
5. Remove the supernatant and add 250 µl of 70% ethanol.
6. Centrifuge for 3-5 minutes.
7. Remove supernatant and repeat 70% ethanol wash.
8. Remove supernatant completely.
9. Dry samples to remove ethanol.
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Appendix vi: Variant Calling Files filter settings
In order to be included, sequences must be:
1. SNP posterior probability higher than 0.95
2. Number of variant reads greater than 3
3. Variant read ratio greater than 0.1
4. All variants are in a single strand direction
5. Total coverage must be greater than 30
6. Total coverage must be less than 100,000
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